Alcon delivered third-quarter results that outpaced consensus on both the top and bottom lines, yet the market responded negatively after the company tightened its outlook for the full year.
For the quarter, Alcon reported adjusted earnings per share of $0.91, above the analyst consensus of $0.88. Revenue reached $2.7 billion, a 5% increase from the prior year and slightly higher than the $2.69 billion estimate.
Despite the beat, Alcon reduced its guidance for the year. The company now expects sales growth of approximately 6% on a constant currency basis, narrowed from the prior range of 5% to 7%. The outlook for core diluted earnings per share growth was also tightened to a 12% to 14% range, down from the previous 12% to 15% span.
Company leadership reiterated progress toward multi-year objectives while acknowledging headwinds. "We remain on track for our 2026 objectives with year-to-date sales growth of six percent and double-digit core EPS growth, despite some specific areas of competitive pressure," said David J. Endicott, Alcon’s Chief Executive Officer.
Business-line performance
The Surgical segment generated $1.5 billion in sales, up 4% year over year. Within Surgical, Implantables sales declined 2%, a drop the company attributed to competitive pressures in the U.S. intraocular lens (IOL) market. Even so, the PanOptix Pro product showed strong performance. Equipment sales in Surgical rose 11%, supported by launches including the Unity platform and Valeda.
Vision Care sales were $1.2 billion, up 6% from the prior year.
Margins, returns and efficiency programs
Alcon reported a core operating margin increase of 1.6 percentage points to 21.8%. Management cited a combination of a $58 million tariff refund, manufacturing efficiencies, and price increases as contributors to margin expansion. On a GAAP basis, diluted earnings per share were $0.54, up 13% from the prior year.
The company repurchased $210 million of shares during the quarter and has returned $748 million to shareholders year-to-date. Alcon also expanded its efficiency measures program and is targeting approximately $130 million in run-rate savings.
Market reaction and outstanding questions
Shares fell roughly 5% on the news, reflecting investor focus on the tightened guidance despite the quarter's upside. The company and its published commentary highlighted competitive dynamics in parts of the Surgical franchise as a reason for the narrower outlook.
Certain questions raised alongside the report remain unaddressed in the company's public disclosures: specifically, how much of the quarter's earnings beat was anticipated by the market and whether analysts have revised their forecasts to reflect the tightened guidance. The company did not provide analyst revisions or quantified market expectations in the information accompanying its release.
Overall, Alcon's quarter combined an upside on reported results with caution on forward guidance, leaving investors to weigh current operational momentum against near-term competitive pressures.